[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 2, 1982

Cost-effectiveness of PUVA Therapy: Further Considerations-Reply

JAMA. 1982;247(13):1808-1809. doi:10.1001/jama.1982.03320380014009

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.—  Dr Abel and and her colleagues are correct in pointing out that our article did not quantify the cost of diagnosing and treating skin cancers attributable to PUVA, the cost of reduced immune responsiveness, and the cost relating to possible cataract formation. Such costs were mentioned only because they were small compared with the costs of repeated PUVA treatments and the costs of hospitalizations for treatment of psoriasis. Furthermore, they were more than counterbalanced by the costs of alternative therapy (such as topical agents), lost time from work, and physician office fees.The ultimate place for PUVA in the treatment of psoriasis will depend on its long-term toxic effects. With the help of Dr Abel and other investigators, continued study for at least another five years of the original cohort of patients treated with PUVA should help provide a better assessment of long-term risks. However, it is not